23 studies found for: Open Studies | "Hyperlipoproteinemia Type II"
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Developing and Implementing Familial Hypercholesterolemia Registry
Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
The Spanish Familial Hypercholesterolaemia Cohort Study
A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).
Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders
Russian Familial Hypercholesterolemia Registry
French Observatory of Familial Hypercholesterolemia in Cardiology
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia
MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)
Atherosclerosis in Familial Hypercholesterolemia
|19||Not yet recruiting||
Effects of Lomitapide on Carotid and Aortic Atherosclerosis
|20||Not yet recruiting||
Lp(a) and Aortic Valve Calcification
† Study has passed its completion date and status has not been verified in more than two years.